MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

ACADIA Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

22.56 -0.18

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

22.4

Max

22.82

Schlüsselkennzahlen

By Trading Economics

Einkommen

-125M

19M

Verkäufe

-15M

244M

KGV

Branchendurchschnitt

15.978

39.857

Gewinnspanne

7.771

Angestellte

653

EBITDA

7.1M

19M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+28.87% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

374M

3.7B

Vorheriger Eröffnungskurs

22.74

Vorheriger Schlusskurs

22.56

Nachrichtenstimmung

By Acuity

14%

86%

17 / 376 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

ACADIA Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Juli 2025, 21:01 UTC

Ergebnisse

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18. Juli 2025, 20:50 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

18. Juli 2025, 20:50 UTC

Market Talk
Ergebnisse

Auto & Transport Roundup: Market Talk

18. Juli 2025, 20:50 UTC

Market Talk
Ergebnisse

Basic Materials Roundup: Market Talk

18. Juli 2025, 20:46 UTC

Ergebnisse

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18. Juli 2025, 20:39 UTC

Akquisitionen, Fusionen, Übernahmen

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18. Juli 2025, 20:36 UTC

Ergebnisse

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18. Juli 2025, 20:16 UTC

Akquisitionen, Fusionen, Übernahmen

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18. Juli 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18. Juli 2025, 20:02 UTC

Market Talk

Gold Higher to Close Out Week -- Market Talk

18. Juli 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18. Juli 2025, 19:06 UTC

Market Talk

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18. Juli 2025, 18:24 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18. Juli 2025, 18:19 UTC

Ergebnisse

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18. Juli 2025, 18:11 UTC

Akquisitionen, Fusionen, Übernahmen

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18. Juli 2025, 18:11 UTC

Ergebnisse

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18. Juli 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18. Juli 2025, 16:29 UTC

Market Talk

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18. Juli 2025, 16:28 UTC

Akquisitionen, Fusionen, Übernahmen

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18. Juli 2025, 16:22 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18. Juli 2025, 16:20 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

18. Juli 2025, 16:20 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

18. Juli 2025, 16:20 UTC

Market Talk
Ergebnisse

Auto & Transport Roundup: Market Talk

18. Juli 2025, 16:20 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Energy & Utilities Roundup: Market Talk

18. Juli 2025, 16:20 UTC

Market Talk
Ergebnisse

Basic Materials Roundup: Market Talk

18. Juli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18. Juli 2025, 16:04 UTC

Ergebnisse

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18. Juli 2025, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

18. Juli 2025, 15:58 UTC

Market Talk

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18. Juli 2025, 15:47 UTC

Market Talk
Ergebnisse

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Peer-Vergleich

Kursveränderung

ACADIA Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

28.87% Vorteil

12-Monats-Prognose

Durchschnitt 29.06 USD  28.87%

Hoch 39 USD

Tief 15 USD

Basierend auf 19 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für ACADIA Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

19 ratings

13

Buy

5

Halten

1

Sell

Technischer Score

By Trading Central

14.845 / N/AUnterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Neutral Evidence

Stimmung

By Acuity

17 / 376 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.